Lycium Barbarum Polysaccharide‐Derived Nanoparticles Protect Visual Function by Inhibiting RGC Ferroptosis and Microglial Activation in Retinal Ischemia‒Reperfusion Mice

Author:

Ni Yueqi1,Hu Yuanyuan1,Zhu Lijia1,Jiang Xulin2,Zhang Hong1,Liu Jia3,Zhao Yin1ORCID

Affiliation:

1. Department of Ophthalmology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430030 China

2. Key Laboratory of Biomedical Polymers of Ministry of Education and Department of Chemistry Wuhan University Wuhan 430072 China

3. Research Center for Tissue Engineering and Regenerative Medicine Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Abstract

AbstractRetinal ischemia‒reperfusion (IR) is a major contributor to vision impairment and irreversible vision loss due to retinal ganglion cell (RGC) injury or loss. Contemporary therapeutic approaches predominantly focus on the amelioration of symptoms rather than addressing the fundamental etiological factors. Oxidative stress is a notable feature and an important mediator of IR damage. Lycium barbarum polysaccharide (LBP), the main active ingredient of Lycium barbarum, has various pharmacological effects, including antioxidation, immunoregulation, and neuroprotective effects. In this study, the ROS‐consumable moiety phenylboronic acid pinacol ester (PBA) is introduced to LBP molecules, which can self‐assemble into nanoparticles in aqueous solution. This nanoparticle (termed PLBP) can reduce the cellular ROS levels and enhance the antioxidant capability of RGCs by activating the NRF2 pathway, thus protecting RGCs from ferroptosis and preserving visual function in response to IR injury. PLBP also reduces neuroinflammation by inhibiting the ability of microglia to phagocytose, migrate, secrete inflammatory cytokines, and activate the NF‐κB pathway. In conclusion, this approach can be used as an inspiration for the future development of neuroprotective drugs.

Funder

National Natural Science Foundation of China

Tongji Hospital

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3